Antitumour activity of yogurt: study of 
possible immune mechanisms

Perdigón, Gabriela; Valdéz, Juan Carlos; Rachid, Mirta

doi:10.1017/s0022029997002604

Cited by 59 publications

(41 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We observed that yoghurt supplements every 10 days for 6 months inhibited tumour development. We suggested that one of the mechanisms by which yoghurt exerts antitumour activity is through its immunomodulatory response mediated by a severe reduction (down regulation) of the inflammatory response induced by the carcinogen (Perdigó n et al, 1998;Valdez et al, 1997). However, we cannot ignore the possibility that the intestinal inflammatory process preceding tumour development may be due to change in the epithelial cell induced by the carcinogen which enters the intestine as glucuronide, and where the normal microflora has the important role of deconjugating this compound by enzymes synthesized by gut microorganisms.…”

Section: Yoghurt As Immunomodulator In Colon Cancer Preventionmentioning

confidence: 99%

Role of yoghurt in the prevention of colon cancer

et al. 2002

View full text Add to dashboard Cite

The beneficial effect of yoghurt consumption on health and on the improvement of the mucosal immune system is well established, as is the diet-associated risk of colon cancer. In an experimental model in BALB=c mice we demonstrated that yoghurt added to the diet for 10 consecutive days, with the procedure repeated each 10 days for 6 months, inhibited the development of a colorectal carcinoma induced by 1,2 dimethylhydrazine (DMH). The immunoregulatory mechanisms involved in the inhibition of tumour growth by yoghurt were also examined in these studies. We determined B lymphocytes IgA þ and IgG þ , as well as CD4 þ and CD8 þ T cells in the large intestine. We measured cellular apoptosis and the cytokines TNF-a, IFN-g and IL-10. An increase in the number of IgA þ (P < 0.01) was observed, but not in IgG þ (P < 0.01), or in the CD4 þ population (P < 0.01) in the mice treated with DMH and yoghurt. While in the group with the carcinogen there was an enhancement in the IgG þ B cells (P < 0.01) and CD8 þ T cells (P < 0.01). Yoghurt increased the number of apoptotic cells and induced IFN-g and TNFa cytokine release, their production being regulated by an increase in IL-10 (P < 0.001). We demonstrated that yoghurt may exert antitumour activity by a decrease in the inflammatory immune response mediated by IgA þ increase, apoptosis induction and IL-10 release.

show abstract

Section: Yoghurt As Immunomodulator In Colon Cancer Preventionmentioning

confidence: 99%

Role of yoghurt in the prevention of colon cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…In week 8, yogurt or supernatant were again added to the diet for 10 consecutive days. This procedure was repeated every 10 days during the 16 weeks of experimentation, according to a previous study (3). The animals were housed individually and the amount of yogurt ingested was between 2,5 to 3 mild.…”

Section: Tumor Induction and Feeding Proceduresmentioning

confidence: 99%

“…We also determined that yogurt inhibited an experimental intestinal tumor induced by the carcinogen 1,2 dimethylhidrazine (DMH) in BALB/c mice. We suggested that one of the mechanisms by which yogurt inhibits the establishment and growth of the tumor could be through a down regulation in the inflammatory immune response (3). Macrophages are also involved in the inhibition of tumor.…”

mentioning

confidence: 99%

Effect of Yogurt on the Inhibition of an Intestinal Carcinoma by Increasing Cellular Apoptosis

Rachid¹,

Gobbato²,

Valdéz³

et al. 2002

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Yogurt consumption has been associated with decreased risk of colon cancer. The apoptosis induced by yogurt as a mechanism involved in the inhibition of an experimental intestinal tumor induced by 1,2 dimethylhydrazine (DMH) in BALB/c mice, has been studied. An imbalance between apoptosis and mitosis or cell proliferation is believed to underlie colon cancer development and progression. We determined the effect of yogurt feeding in the induction of apoptosis and the relationship between mitosis and apoptosis in mice injected with the carcinogen DMH and in mice injected with DMH and fed with a diet supplemented with yogurt. The percentage of mitotic and apoptotic cells was analyzed every 2 weeks from week 8 to 16. They were analyzed on histological slices from the large intestine by colchicine, or Tunel test for mitosis and apoptosis determination, respectively. An increase in the mitosis during the first 4 weeks of tumor development with apoptosis negative and severe dysphasia, was observed in animals treated with the carcinogen. In those animals that received DMH and were given yogurt, a moderate cell proliferation with a significant increase in the number of apoptotic cells was determined. The increase in the apoptotic activity was also observed in the group of animals that received only a diet supplemented with yogurt. The results suggest that yogurt would influence the balance between mitosis and apoptosis, which was modified during the carcinogenesis process, by increasing cellular apoptosis. Dietary supplementation of yogurt may play a role in modulating cell proliferation or apoptosis during the development of colorectal carcinoma.

show abstract

“…There have been numerous reports on the potentially beneficial effects of consumption of yoghurt and dairy products containing lactic acid bacteria by either patients with allergic diseases (Wheeler et al, 1997a,b;Van de Water et al, 1999) healthy volunteers (Arunachalam et al, 2000;Chen et al, 1999;Halpern et al, 1991;Yoon et al, 1999;Solis-Pereyra et al, 1997) and laboratory animals (Solis Pereyra et al, 1997;Perdigon et al, 1998;Ha et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Effects of dietary yoghurt on immunological and clinical parameters of rhinopathic patients

et al. 2002

View full text Add to dashboard Cite

Objectives: To examine the immunological and clinical influence of 4 months' feeding with either yoghurt or partially skimmed milk or nothing, on 20 volunteers. Subjects: Thirteen subjects had a demonstrated allergic rhinopathy and seven were healthy subjects and participated as controls.Research design: Either a group of seven or a group of six rhinopathic patients were fed either 450 g yoghurt or 450 g partially skimmed milk, respectively, for 4 months between March and October 1999. All subjects maintained their usual diet throughout the study. Peripheral blood mononuclear cells (PBMC) were isolated before and after the experimental period and cultured for periods of 40 and 64 h. Proliferation index assay and release of IFNg and IL-4 without and with PHA stimulation were assessed. Allergic rhinopathy was evaluated before and after the 4 months period by performing the nasal functionality tests (Active Anterior Rhinomanometry, Acoustic Rhinometry), the prick test, the nasal specific provocation test (NPT), the dosage of specific IgE blood levels, the evaluation of the symptomatological score and the nasal mucociliary transport test. Results: No significant change of the proliferation index was noted among the three groups. Cultured PBMC of the group fed with yoghurt released more IFNg and less IL-4. Cytokine plasma levels were at and remained at basal levels. Prick test, specific serum IgEs and NPT remained immodified. Muco-ciliary transport time (MCTt) and symptomatological score showed a definitive improvement after yoghurt feeding. Conclusion: Yoghurt feeding appears to improve or prevent allergic recurrences in rhinopatic patients.

show abstract

Antitumour activity of yogurt: study of possible immune mechanisms

Cited by 59 publications

References 1 publication

Role of yoghurt in the prevention of colon cancer

Role of yoghurt in the prevention of colon cancer

Effect of Yogurt on the Inhibition of an Intestinal Carcinoma by Increasing Cellular Apoptosis

Effects of dietary yoghurt on immunological and clinical parameters of rhinopathic patients

Contact Info

Product

Resources

About